{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T04:09:33Z","timestamp":1772683773457,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01002","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T04:43:03Z","timestamp":1568176983000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis"],"prefix":"10.3389","volume":"10","author":[{"given":"Jian-Ge","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Er-Jiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Mei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Bo","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Kun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Chia-mi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Xue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"B1","article-title":"Apigenin modulates insulin-like growth factor axis: implications for prevention and therapy of prostate cancer","volume-title":"Curr. Drug Targets","author":"Babcook","year":"2012"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.nano.2018.05.011","article-title":"Apigenin loaded nanoparticle delayed development of hepatocellular carcinoma in rats","volume":"14","author":"Bhattacharya","year":"2018","journal-title":"Nanomedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14656566.2017.1334764","article-title":"Current and future treatment options for esophageal cancer in the elderly","volume":"18","author":"Bollschweiler","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.21873\/anticanres.12588","article-title":"Multimodal anti-tumor approaches combined with immunotherapy to overcome tumor resistance in esophageal and gastric cancer","volume":"38","author":"Bolm","year":"2018","journal-title":"Anticancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"B6","first-page":"4617","article-title":"IL-6 increases SDCBP expression, cell proliferation, and cell invasion by activating JAK2\/STAT3 in human glioma cells","volume":"9","author":"Cao","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13046-018-0869-1","article-title":"Downregulating CD26\/DPPIV by apigenin modulates the interplay between Akt and Snail\/Slug signaling to restrain metastasis of lung cancer with multiple EGFR statuses","volume":"37","author":"Chang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1172\/JCI120855","article-title":"Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers","volume":"129","author":"Chappell","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.03.020","article-title":"IL-6 promotes endometrial cancer cells invasion and migration through signal transducers and activators of transcription 3 signaling pathway","volume":"215","author":"Che","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","article-title":"Interleukin-6 as a therapeutic target in human ovarian cancer","volume":"17","author":"Coward","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10549-013-2488-z","article-title":"The role of intratumoral and systemic IL-6 in breast cancer","volume":"138","author":"Dethlefsen","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer","volume":"26","author":"Dijkgraaf","year":"2015","journal-title":"Ann. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/1078-0432.CCR-09-3122","article-title":"Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer","volume":"16","author":"Dorff","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1128\/MCB.9.5.1908","article-title":"Identification of cis-acting sequences responsible for phorbol ester induction of human serum amyloid A gene expression via a nuclear factor kappaB-like transcription factor","volume":"9","author":"Edbrooke","year":"1989","journal-title":"Mol. Cell Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ctrv.2018.10.009","article-title":"Third line treatment of advanced oesophagogastric cancer: a critical review of current evidence and evolving trends","volume":"71","author":"Edwards","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1096\/fj.04-2175com","article-title":"Apigenin inhibits VEGF and HIF-1 expression via PI3K\/AKT\/p70S6K1 and HDM2\/p53 pathways","volume":"19","author":"Fang","year":"2005","journal-title":"FASEB J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/carcin\/bgl205","article-title":"Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression","volume":"28","author":"Fang","year":"2007","journal-title":"Carcinogenesis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.2174\/1381612822666151124234417","article-title":"Interleukin-6: a critical cytokine in cancer multidrug resistance","volume":"22","author":"Ghandadi","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"B19","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.V1071466","article-title":"Transcriptional regulation of the interleukin-6 gene in mesangial cells","volume":"10","author":"Grassl","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","article-title":"Interleukin-6 signaling pathway in targeted therapy for cancer","volume":"38","author":"Guo","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12943-019-0972-8","article-title":"Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer","volume":"18","author":"Ham","year":"2019","journal-title":"Mol. Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.3390\/ijms13067271","article-title":"Oral administration of apigenin inhibits metastasis through AKT\/P70S6K1\/MMP-9 pathway in orthotopic ovarian tumor model","volume":"13","author":"He","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.3748\/wjg.14.2187","article-title":"Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence","volume":"14","author":"Hoensch","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1021\/acs.jafc.6b00766","article-title":"Chrysin, Abundant in Morinda citrifolia fruit water-EtOAc extracts, combined with apigenin synergistically induced apoptosis and inhibited migration in human breast and liver cancer cells","volume":"64","author":"Huang","year":"2016","journal-title":"J. Agric. Food Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1128\/MCB.10.6.2757","article-title":"Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene","volume":"10","author":"Isshiki","year":"1990","journal-title":"Mol. Cell Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/mnfr.201300307","article-title":"Flavonoid apigenin modified gene expression associated with inflammation and cancer and induced apoptosis in human pancreatic cancer cells through inhibition of GSK-3beta\/NF-kappaB signaling cascade","volume":"57","author":"Johnson","year":"2013","journal-title":"Mol. Nutr. Food Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3892\/ijo.2014.2339","article-title":"Apigenin-induced apoptosis is enhanced by inhibition of autophagy formation in HCT116 human colon cancer cells","volume":"44","author":"Lee","year":"2014","journal-title":"Int. J. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41420-018-0124-8","article-title":"Apigenin suppresses the stem cell\u2013like properties of triple-negative breast cancer cells by inhibiting YAP\/TAZ activity","volume":"4","author":"Li","year":"2018","journal-title":"Cell Death Discov."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019139","article-title":"MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.biopha.2018.09.177","article-title":"The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer","volume":"108","author":"Masjedi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.cellsig.2006.05.019","article-title":"Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway","volume":"18","author":"Meng","year":"2006","journal-title":"Cell Signal."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1517\/14656566.2013.801454","article-title":"Treatment options for esophageal squamous cell carcinoma","volume":"14","author":"Nakajima","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/jcb.27575","article-title":"Apigenin as an effective anticancer natural product: spotlight on TRAIL, WNT\/beta-catenin, JAK-STAT pathways, and microRNAs","volume":"120","author":"Ozbey","year":"2018","journal-title":"J. Cell Biochem."},{"key":"B35","first-page":"1137","article-title":"[Effect of apigenin on proliferation and apoptosis of human lung cancer NCI-H460 cells]","volume":"33","author":"Pan","year":"2013","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"B36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1875-5364(17)30052-3","article-title":"Apigenin\u2019s anticancer properties and molecular mechanisms of action: recent advances and future prospectives","volume":"15","author":"Salmani","year":"2017","journal-title":"Chin. J. Nat. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1535-7163.MCT-13-0066","article-title":"Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263","volume":"12","author":"Shao","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.2169\/internalmedicine.0677-17","article-title":"Esophageal carcinosarcoma that was diagnosed as a granulocyte-colony stimulating factor and interleukin-6\u2013producing tumor with a tumor fever","volume":"57","author":"Shioga","year":"2018","journal-title":"Intern. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/carcin\/bgt316","article-title":"Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K\/Akt\/FoxO pathway","volume":"35","author":"Shukla","year":"2014","journal-title":"Carcinogenesis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"29820","DOI":"10.18632\/oncotarget.25661","article-title":"Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer","volume":"9","author":"Vainer","year":"2018","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004064.pub4","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","article-title":"MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer","volume":"18","author":"Weng","year":"2019","journal-title":"Mol. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.1021\/acs.jafc.8b02351","article-title":"Apigenin suppresses the IL-1beta\u2013induced expression of the urokinase-type plasminogen activator receptor by inhibiting MAPK-mediated AP-1 and NF-kappaB signaling in human bladder cancer T24 cells","volume":"66","author":"Xia","year":"2018","journal-title":"J. Agric. Food Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jmcb\/mjs049","article-title":"A regulatory circuit of miR-148a\/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1","volume":"5","author":"Xu","year":"2013","journal-title":"J. Mol. Cell Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/nar\/gkr730","article-title":"MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis","volume":"40","author":"Xu","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13046-018-0929-6","article-title":"Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects","volume":"37","author":"Xu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev.nutr.21.1.381","article-title":"Inhibition of carcinogenesis by dietary polyphenolic compounds","volume":"21","author":"Yang","year":"2001","journal-title":"Annu. Rev. Nutr."},{"key":"B49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"11228","DOI":"10.18632\/oncotarget.14495.","article-title":"IL-6\/STAT3\/TWIST inhibition reverses ionizing radiation-induced EMT and radioresistance in esophageal squamous carcinoma","volume":"8","author":"Zang","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T03:51:54Z","timestamp":1664337114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":50,"alternative-id":["10.3389\/fphar.2019.01002"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01002","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"article-number":"1002"}}